Fasen­ra shows pos­i­tive PhI­II topline da­ta for nasal polyps, tight­en­ing race with GSK's Nu­cala

The high­ly con­test­ed res­pi­ra­to­ry field just got even tighter Thurs­day.

As­traZeneca re­vealed topline da­ta for a Phase III tri­al Thurs­day eval­u­at­ing its Fasen­ra asth­ma ther­a­py in a new in­di­ca­tion — chron­ic rhi­nos­i­nusi­tis with nasal polyps. The British drug­mak­er said the drug met both co-pri­ma­ry end­points in pa­tients who did not see im­prove­ment on the stan­dard of care, re­duc­ing the size of nasal polyps and im­prov­ing nasal block­age.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER